NYSE:LHHealthcare
Labcorp (LH): Evaluating the Stock’s Value After Launching a Groundbreaking Alzheimer’s Blood Test
Labcorp Holdings just made headlines with the rollout of the FDA-cleared Lumipulse pTau-217/Beta Amyloid 42 Ratio test, the first blood-based diagnostic of its kind to aid Alzheimer’s disease diagnosis. This isn’t just another product launch. For investors, the move addresses a real need in the market by offering a more affordable, accessible, and less invasive alternative to lumbar punctures and PET scans. With updated clinical guidelines now supporting blood-based biomarkers, Labcorp’s...